



## From the Desk of President

Dear Friends

The bulk drug industry has been navigating a challenging environment over the past year, driven by unpredictable conditions in global markets, particularly in the United States, one of our key export destinations. The situation has been further compounded by ongoing unrest in West Asia, adding pressure on supply chains and input costs.

Amid these headwinds, the proactive approach of the Government of India is commendable. Multiple departments engaged closely with our Association to assess the impact of the West Asia conflict on the industry. This was not limited to consultation alone, but was followed by timely intervention. Recognizing the steep rise in prices of key chemicals and solvents, the Government announced a three-month waiver of customs duty on select critical inputs for the bulk drug industry. The effectiveness of this measure will become clearer in the coming weeks, but it is undoubtedly a step in the right direction.

Globally, there is a clear shift towards self-reliance in the pharmaceutical sector, with many countries adopting policies aimed at securing domestic supply chains and reducing import dependence. This evolving landscape presents a significant opportunity for India.

With its strong manufacturing base, skilled workforce, and cost competitiveness, the Indian bulk drug industry is well-positioned to play a pivotal role in supporting global pharmaceutical supply chains.

At the same time, these developments highlight the need for continued focus on strengthening domestic capabilities, improving cost efficiencies, and enhancing backward integration. As an Association, we remain committed to working closely with the Government and all stakeholders to ensure that the industry's concerns are effectively addressed and its growth potential fully realized.

With sustained collaboration and a forward-looking approach, I am confident that the industry will successfully navigate the current uncertainties and emerge stronger in the months ahead.

With best regards

Ch A P Rameswara Rao  
National President

In this Bulletin  
you can expect

### Global Pharma News

New Drug  
Developments,  
Investments & JVs  
Drug Approvals,

### BDMAI Activities

Representations  
Circulars  
Events  
Govt Notifications

### Technical / Commercial Articles

Data of  
Import & Export  
of Bulk Drugs

## New Drug Developments:

### Bioxytran reports positive phase 1b/2a results for antiviral ProLectin-M

Bioxytran has announced encouraging results from a randomized, double-blind, placebo-controlled phase 1b/2a study of its oral antiviral ProLectin-M in patients hospitalised with mild to moderate COVID-19. The company said the highest evaluated dose of 16,800 mg/day led to significantly earlier viral clearance and faster clinical improvement by day 5 compared with placebo, with 90% of patients clearing the virus versus 20% in the placebo arm. By day 7, viral clearance was seen across all study groups, which the company noted is consistent with the expected natural course of infection. No serious adverse events were reported and no patients discontinued treatment because of side effects, supporting what Bioxytran described as a favourable safety and tolerability profile

Pharma Time 2.3.2026  
[Read more](#)

### Theolytics awarded €8 million Horizon Europe grant to fund ovarian cancer study

The Oxford-based biotechnology company Theolytics has been awarded €8 million in non-dilutive grant funding from Horizon Europe 2025. This competitive award – following a rigorous review process – is designed to support the company’s phase 2 OCTOPOD-IV clinical trial. The study evaluates THEO-260, a novel therapeutic candidate developed to treat advanced ovarian cancer by killing both cancer cells and cancer-associated fibroblasts. The

grant application was coordinated with several international partners, including The Institute of Cancer Research in London and the Clínica Universidad de Navarra. Two thirds of the funds will be received directly by Theolytics to advance the phase 2a expansion trial, which focuses on high-grade serous ovarian or endometrioid cancer.

Pharma Times 4.3.2026  
[Read More](#)

### Alzecure shares new preclinical data on NeuroRestore ACD856 at AD/PD conference

AlzeCure Pharma has released new preclinical findings for its lead Alzheimer’s drug candidate, NeuroRestore ACD856, following a presentation at the AD/PD 2026 international conference. The full presentation is now available on the company’s website and highlights emerging evidence supporting the compound’s mechanism of action and therapeutic potential. Cristina Parrado-Fernández, senior scientist at AlzeCure, said: ‘These new data with ACD856 show that the compound has a clear biological effect on NGF and BDNF signaling mediated by TRK receptors. These systems play an important role in the normal function of neurons in the brain, and improved signaling leads to positive effects in disturbed systems, such as improved memory function and antidepressant effects.’

Pharma Times 19.3.2026  
[Read More](#)

## Tozorakimab shows significant benefit in two major COPD trials

Positive high-level results from the phase 3 OBERON and TITANIA trials indicate that tozorakimab achieved statistically significant and clinically meaningful reductions in the annualised rate of moderate to severe COPD exacerbations compared with placebo. The findings applied both to the primary population of former smokers and to the overall population, which included former and current smokers, with patients spanning all blood eosinophil counts and all stages of lung function severity. According to the data, tozorakimab was generally well tolerated with a favourable safety profile

Pharma Times 30.3.2026  
[Read More](#)

## Drug Approvals:

### Incyte treatment for advanced anal cancer approved in Europe

Incyte has received European Commission approval for Zynyz (retifanlimab) in combination with carboplatin and paclitaxel as a first-line treatment for adults with metastatic or inoperable locally recurrent squamous cell carcinoma of the anal canal. Bill Meury, President and Chief Executive Officer at Incyte, said: “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades.” He added that “as the first PD-1 immunotherapy approved in Europe in combination with platinum-based chemotherapy in the first-line setting, Zynyz helps expand the standard-of-care options available to clinicians and

underscores our commitment to delivering innovative medicines that can have an impact for patients.”

Pharma Times 9.3.2026

[Read More](#)

### MHRA approves new treatment for severe alopecia areata

The MHRA has approved deuruxolitinib, marketed as Leqselvi, for the treatment of severe alopecia areata in adults, offering a new therapeutic option for people living with the autoimmune condition. Alopecia areata occurs when the immune system attacks hair follicles, triggering inflammation that leads to hair loss on the scalp, face or other parts of the body. Deuruxolitinib works by reducing the activity of JAK1, JAK2 and TYK2 relative to JAK3 kinases, enzymes involved in the inflammatory process at the hair follicle. By dampening this inflammation, the medicine can support hair regrowth

Pharma Times 12.3.2026  
[Read More](#)

### FDA Approves Avlayah for Treatment of Hunter Syndrome

FDA granted accelerated approval for Avlayah (tvidenofusp alfa-eknm), the first therapy designed to cross the blood-brain barrier and treat the neurological manifestations of Hunter syndrome. In connection with the approval, FDA granted Denali a Rare Pediatric Disease Priority Review Voucher, which may be used to accelerate review of a future application or transferred to another sponsor

Pharma Express Pulse 26.3.2026  
[Read More](#)

## Teva receives FDA approval for Prolia biosimilar

Teva Pharmaceutical has announced the US Food and Drug Administration (FDA) approval for Ponlimsi (denosumab-adet) as a biosimilar to Prolia, alongside the acceptance of its biosimilar candidate applications for Xolair (omalizumab) by both the agency and the European Medicines Agency (EMA). The FDA approval of Ponlimsi is based on a comprehensive evidence package, including analytical and clinical data showing immunogenicity, safety, and similar efficacy to Prolia. Ponlimsi is approved for all indications of the reference product, such as treating postmenopausal women with osteoporosis at high risk of fracture and increasing bone mass in men with osteoporosis.

Pharmaceutical      Technologies      31.3.2026  
[Read More](#)

## Eli Lilly wins FDA approval for weight loss pill, tees up Novo rivalry

The US Food and Drug Administration (FDA) has approved Eli Lilly's orforglipron pill for weight loss, ending Novo Nordisk's first mover advantage in the US after just three months. The oral glucagon-like peptide-1 receptor agonist (GLP-1RA) will be branded under the name Foundayo. Lilly expects to launch the drug on its direct-to-consumer channel by 6 April, with retail pharmacy and telehealth provider availability following soon after. The FDA based its decision on results from the ATTAIN clinical programme, which demonstrated that patients taking the highest dose of Foundayo who remained

on treatment lost an average of 12.4% of their body weight.

Pharmaceutical      Technology  
[Read More](#)

## Johnson & Johnson Wins DARZALEX Self-Administration EU Nod

Johnson & Johnson has received a key regulatory endorsement in Europe, marking a significant shift in how oncology treatments can be administered. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has approved a Type II variation to the label of DARZALEX (daratumumab) subcutaneous (SC) formulation. This update allows patients diagnosed with multiple myeloma, or their caregivers, to administer the therapy from the fifth dose onward, provided this approach is deemed suitable by a healthcare professional and appropriate training has been completed. The decision establishes DARZALEX self-administration as the first instance of an oncology injectable being approved for patient or caregiver use in Europe

World      Pharma      Today  
[Read More](#)

## FDA approves new high dose Spinraza regimen for SMA

Biogen has received approval from the US Food and Drug Administration for a new high dose regimen of Spinraza for the treatment of spinal muscular atrophy. The company said the regimen, which includes 50mg and 28mg doses, was designed to deliver a higher concentration of the drug during both loading and maintenance phases. The approval is based on data from the phase 2/3 Devote study, which evaluated the efficacy and safety of the high dose regimen in both treatment-naïve

patients and those previously treated with Spinraza. The company said the new regimen will be available in the United States in the coming weeks and is already approved in the European Union, Switzerland and Japan.

Pharma Times 1.4.2026

[Read More](#)

## M & A / JVs

### Taiwan Bio partners with Terumo to advance automated Treg manufacturing

Terumo Blood and Cell Technologies has entered a new collaboration with Taiwan Bio Therapeutics to transition regulatory T-cell manufacturing onto the automated Quantum Flex platform, marking a shift away from manual processes toward more scalable and repeatable production. Taiwan Bio is developing the TregCel therapy TRK-001, which is now in multicentre phase 2 trials assessing its potential to prevent graft rejection in kidney transplantation. Under the partnership, the companies will integrate Taiwan Bio's existing phase 2 Treg manufacturing platform with Quantum Flex to create a next-generation engineered Treg process.

Pharma

Times

17.3.2026

[Read More](#)

### Gilead acquires first TCE asset with \$2.2bn Ouro Medicines buyout

Gilead Sciences is set to acquire Ouro Medicines for \$2.2bn, marking the company's first move into the T-cell engager (TCE) space and a deepening of ties with long-term partner, Galapagos. Through this deal, the California-based big pharma company will hand over \$1.68bn upfront, while pledging up to \$500m in milestone payments to absorb the latter's

BCMA/CD3-targeting TCE, gamgertamig (OM336). The therapy is currently in clinical development for antibody-mediated orphan diseases such as immune thrombocytopenia (ITP) and autoimmune haemolytic anaemia (AIHA). According to Citi analysts, Gilead's Ouro acquisition both aligns with the big pharma company's plans to diversify beyond HIV and complements the autoimmune push its subsidiary, Kite is currently making.

Pharmaceutical

Technology

24.3.2026

[Read More](#)

### Merck's strategic shift: acquires Terns for \$6.7bn, targeting dominance in CML

Merck (MSD) announced the \$6.7bn acquisition of Terns Pharmaceuticals via a subsidiary, as part of its strategic preparations for the looming expiration of Keytruda's patent exclusivity. With this strategic move, MSD aims to augment and diversify its oncology portfolio by deepening its footprint in haematological malignancies through the addition of Terns's lead candidate, TERN-701. TERN-701 is an oral allosteric BCR-ABL tyrosine kinase inhibitor (TKI), recently advanced to Phase I/II (CARDINAL) for patients with BCR-ABL1-positive chronic myelocytic leukaemia (CML) who have received at least one prior TKI. Building on encouraging interim data presented at the American Society of Hematology (ASH) 2025, TERN-701 secured FDA fast track designation in December 2025, signalling substantial confidence from both the company and regulators in its therapeutic promise.

Pharmaceutical

Technology

30.3.2026

[Read More](#)

### Otsuka agrees to acquire Transcend Therapeutics for \$1.22bn

Otsuka Pharmaceutical has signed an agreement to fully acquire Transcend Therapeutics through its subsidiary Otsuka America for a potential consideration of \$1.225bn. The deal is anticipated to close in the second quarter of 2026, subject to standard conditions. The acquisition aims to expand Otsuka's portfolio in the psychiatric and neurological fields. Under the agreement, Otsuka will make a \$700m payment to Transcend shareholders upon closing. Additionally, up to \$525m in further payments may be made based on the achievement of future sales milestones related to assets under development.

Pharmaceutical Technology 30.3.2026  
[Read More](#)

### Eli Lilly outlays \$7.8bn to acquire sleep drug biotech Centessa

Eli Lilly will acquire neuroscience specialist Centessa Pharmaceuticals in a deal worth up to \$7.8bn, solidifying the drugmaker's status as one of the most dominant players in the pharma deals arena so far this year. As per the takeover deal, Lilly will acquire UK-based Centessa for \$38 a share, representing a 37% premium on the Nasdaq closing price of \$27.58 on 30 March. Despite the front-loaded nature of the deal, Centessa could also receive an additional \$9 per share in contingent value rights (CVR). Whether that extra \$1.5bn in CVR is added to the deal hinges on three milestones for clemimorexton, Centessa's lead candidate. The asset, formerly known as ORX750, has already demonstrated positive results in Phase II studies across a range of sleep-wake cycle conditions,

including narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia.

Pharmaceutical Technology 1.4.2026  
[Read More](#)

### Adragos Pharma finalise acquisition of manufacturing site

The Maisons-Alfort site is one of Europe's largest manufacturing facilities for sterile injectables, with industrial-scale capacity for pre-filled syringes (PFS), as well as liquids and lyophilised vials. The facility, located in the south-eastern suburbs of Paris, is regularly audited by international health authorities, including ANSM (France), NMPA (China), MFDS (South Korea), and ANVISA (Brazil), and supports the global supply of critical injectable medicines. Dr. Andreas Raabe, founder and CEO of Adragos Pharma, said: "Maisons-Alfort is a landmark acquisition for Adragos and a defining step in our growth journey. We are adding one of Europe's leading sterile manufacturing sites to our network. Our ambition is clear: to invest, scale, and further develop the site into a top-tier fill-finish platform. This transaction is fully aligned with our strategy to secure and expand highly differentiated pharmaceutical manufacturing capacity in Europe

European Pharmaceutical Manufacturer 1.4.2026  
[Read More](#)

### Biocytogen and Sihuan partner to advance new therapeutics for weight loss

Biocytogen has entered a strategic partnership with Sihuan Pharmaceutical to advance new therapeutics across several disease areas, including weight loss. Under the agreement, Biocytogen's fully human antibody discovery platform will be combined with Sihuan Pharmaceutical's capabilities in drug development,

manufacturing, and commercialisation. The collaboration will focus on advanced therapies in multiple disease areas, including weight loss, using the companies' complementary capabilities to support development and potential market progress.

Pharmaceutical      Technology      2.4.2026  
[Read More](#)

## Shionogi Enters \$2.5 Billion Agreement to Acquire All Rights to Radicava

Shionogi completed the acquisition of global rights to Radicava (edaravone), an approved treatment for amyotrophic lateral sclerosis. The acquisition builds on the originally announced terms of the agreement back from December 22, 2025, and will see Shionogi pay \$2.5 billion to Tanabe Pharma Corporation, while establishing itself as a commercially active rare disease company in the process

Pharma Express Pulse 2.4.2026  
[Read More](#)

## Aspect Biosystems receives funding for cellular medicine project

Aspect Biosystems has secured a C\$79m(\$56.6m) investment from the Government of Canada to support a C\$280m multi-year project aimed at advancing its pipeline of bioengineered cellular medicines for endocrine and metabolic diseases. The project will enhance Aspect Biosystems' clinical development capabilities and bolster its integrated platform for developing and manufacturing advanced cellular medicines. The investment is in addition to the C\$200m co-investment previously announced with the Government of Canada and Province of British Columbia in 2024

Pharmaceutical      Technology      6.4.2026  
[Read More](#)

# ASSOCIATION ACTIVITIES

## Circulars

BDMAI issued the following circulars to the Members:

Sl. No.	Date	Subject
1	3.3.2026	A Free Skill Development Course on Environmental Sustainability for MSME organized by ICC
2	6.3.2026	Technical Meet on 'Strategies for Sustainable Waste Water Treatment & ZLD Systems – March 12-13 2026
3	6.3.2026	BDMAI's proposal to organize a Pavilion at CPhI India 2026 – Request for Expression of Interest to participate in the pavilion
4	8.3.2026	Greening of MSMEs – Free Technical Assistance – An initiative of Telangana State under RAMP Programme
5	24.3.2026	Interactive Meeting with Commerce Secretary, Government of India

## Events & Meetings:

### Meeting with Member Secretary, TSPCB

Some of the Executive Committee Members of BDMAI met the Member Secretary of the Pollution Control Board, Telangana, on 18th March 2026 and submitted a representation seeking certain clarifications. They also requested that changes in product mix be considered as an amendment under Consent to Operate (CTO) and that the application process for the same be made available online.



# ASSOCIATION ACTIVITIES

## Skill Development programme on Environmental Sustainability:

Indian Chemical Council organized a free Skill Development Programme on Environmental Sustainability for MSMEs on 23.3.2026. BDMAI circulated about the programme among its members. Many of BDMAI members participated in the event. Executive Director participated as one of the keynote Speakers.



## Representations

BDMAI submitted the following representations to various Government agencies:

Sl. No.	Date	Subject
1	25.3.2026	Requested Government of Andhra Pradesh to provide details of land available for allotment to RED category industries as many of our members are looking for land for setting up manufacturing facilities. Click <a href="#">HERE</a> for the detailed representation
2	26.3.2026	Submitted Representations to PCBs of both Telangana and Andhra Pradesh requesting them to provide some clarifications and also consider the change in product mix as an amendment to CFO. Please click <a href="#">HERE</a> to see the representation
3	4.4.2026	Submitted a representation to the Commerce Secretary, Ministry of Commerce, during his visit to Hyderabad on 4.4.2026 requesting him to take necessary action to curb abnormal rise in the price of raw materials required for bulk drug industry. Click <a href="#">here</a> for the detailed representation

## Important Govt. Notifications

### Basic Customs Duty exempted for imports of 40 key petrochemicals and polymers into India

The Ministry of Finance, vide Notification No. 12/2026-Customs dated 1st April 2026, has exempted Basic Customs Duty on imports of certain petrochemicals & polymers into India. The exemption has been allowed in public interest, and will come into force on 2nd April and remain in force till 30th June 2026. Click [here](#) for BDMAI circular along with notification.

# ASSOCIATION ACTIVITIES

## **Procedure for issue of Written Confirmations Streamlined**

CDSCO streamlined the procedure for issue of Written Confirmations required for export of Active Substances to the EU countries. Please click [here](#) for a detailed circular issued by CDSCO

## **Launch of Support for Emerging Export Opportunities**

DGFT has implemented Emerging Export Opportunities under Export Promotion Mission (EPM) – Niryat Protsahan with immediate effect. The intervention will help MSMEs, which are involved in international value chains, access trade finance for exports to under-served markets and boost competitiveness through non-recourse trade finance instruments from banks. The Policy is available at the [link](#) herein.

## **Extension in the Export Obligation period of specified Advance and EPCG Authorisations**

In view of the prevailing geopolitical developments affecting international shipping routes and global supply chains, and with a view of facilitating exporters, the export obligation period or block-wise export obligation period in respect of specified Advance Authorisations and EPCG Authorisations expiring between 1st March 2026 and 31st May 2026 have been automatically extended up to 31st August 2026 without payment of composition fee. This relaxation is in addition to the facility for extension of obligation period, which is already available under Foreign Trade Policy upon payment of composition fees.

## **Time-limited support for exporters in view of geopolitical disruptions in the Gulf and West Asia Maritime Corridor**

DGFT has notified that a time-limited relief intervention under the Export Promotion Mission has been implemented through the Export Credit Guarantee Corporation of India (ECGC), in order to address elevated export risks arising from geopolitical disruptions in the Gulf and West Asia maritime corridor. For further details, refer to the [link](#) herein.

## **Amendments to Guidelines for Interest Subvention Support for Pre and PostShipment Export Credit under Export Promotion Mission – Niryat Protsahan (20 Mar)**

The Directorate General of Foreign Trade has issued certain amendments and insertions in the guidelines of Interest Subvention Support for Pre- and Post-Shipment Export Credit under Export Promotion Mission (EPM). For complete details, refer to the [link](#) herein.

# ASSOCIATION ACTIVITIES

## **India and Chile review progress of trade negotiations for the India-Chile CEPA**

India and Chile reviewed the progress of negotiations on a proposed Comprehensive Economic Partnership Agreement (CEPA) during a bilateral meeting. Both sides have discussed ways to accelerate talks and work towards an early conclusion of the agreement. The Department of Commerce has stated that the ongoing discussions focus on strengthening bilateral economic cooperation as the proposed agreement aims to cover a wider range of areas, including digital services, investment promotion, MSME cooperation, and trade in critical minerals.

## **India and Canada sign Terms of Reference for a CEPA**

India and Canada have signed the Terms of Reference (ToR) for negotiations on a CEPA, marking a significant step in advancing bilateral economic ties. The ToR has been finalised following high-level discussions between Prime Ministers of both countries, marking the official launch of negotiations. However, concerns have been raised over the timeline as many expect the negotiations to be stalled on account of the middle east conflict.

## **India signs Terms of Reference (ToR) with the Philippines and Maldives**

India has signed a separate ToR with the Philippines and Maldives to initiate formal negotiations on new trade agreements, marking fresh efforts to expand its network of economic partnerships. With the Philippines, India aims to begin negotiations for a Preferential Trade Agreement (PTA), while negotiations with Maldives would focus on a broader Free Trade Agreement (FTA).

## **Initiation of anti-absorption review of anti-dumping duty imposed on imports of Insoluble Sulphur from China.**

The DGTR initiated an anti-absorption review of anti-dumping duty imposed on imports of Insoluble Sulphur from China, pursuant to an application filed by OCCL Limited. The Authority prima facie noted that the export price of the product under consideration has declined in the present absorption investigation period compared to the original period of investigation, despite an increase in raw material and utility costs resulting in a higher cost of production. The dumping margin and injury margin have increased.



**Mr. Babu P**

Head - Innovation and Technology  
Thermax Cooling and Heating Business

## **Cutting Costs and Carbon in India's API Pharma Sector**

*How hybrid heat pumps help manufacturers reduce energy costs, meet sustainability targets, and stay competitive.*

India is the world's third-largest pharmaceutical API producer, supplying over half of WHO prequalified Active Pharmaceutical Ingredients (APIs), economically, across the globe including the US and Europe. This success is built on cost-efficient manufacturing. But today, that model is under pressure. Rising energy costs, greener supply chain demands, and tightening regulations mean utility efficiency is no longer just operational; it's a business imperative.

### **The Challenges squeezing API manufacturers**

**Energy Drain and Cost Explosion:** API production runs 24/7 and requires continuous heating for reactions, distillation, and drying. Most facilities still rely on coal or fuel oil, making energy one of the largest expenses. Equipment fouling and complex fluid systems reduce efficiency and increase maintenance and contamination risks.

**Water Crisis and ZLD Compliance Strain:** Pharmaceutical synthesis uses large volumes of water and generates significant effluent. Many plants operate in water-scarce regions, face shortages, use systems that lead to water loss and inefficiencies. Strict pollution norms require Zero Liquid Discharge (ZLD) systems to treat effluent wastewater, increasing compliance costs and operational risks.

**Environmental Mandates and ESG Enforcement:** Global buyers now consider ESG performance when choosing suppliers. Many European companies require Scope 1 and 2 emissions data, at the same time stricter EU and US regulations, FDA/EMA audits, and SEBI's sustainability reporting rules (BRSR) are raising compliance expectations, making sustainability essential to maintain market access.

**Compliance Costs Crushing Profitability:** Amid rising global competition and pressure on margins, utilities like power, steam, and water make up a large part of operating costs. Increasing coal prices, labour shortages, and stricter regulations add to this challenge. At the same time, inefficient steam systems, energy losses, high water usage, and heavy chemical consumption make it essential for companies to optimise their utility infrastructure to control costs and improve efficiency.

### **The Strategic Opportunity: Reimagining Utilities for Sustainable Growth**

Pharmaceutical manufacturers are rethinking utilities via waste heat recovery, smart water systems and digital monitoring to cut costs and to reduce emissions. Once treated as background infrastructure, utilities now directly shape regulatory standing and profitability, pushing manufacturers to optimise every resource.

### **Hybrid Heat Pumps: Smart Design Driving Energy and Water Efficiency**

Hybrid heat pumps are transforming pharmaceutical manufacturing by addressing major issues such as high energy consumption, water wastage, dependence on fossil fuels, contamination risks, limited digital monitoring and carbon/ESG pressures – all through one integrated system. Hybrid heat pumps combine absorption and compression technologies into one smart unit, they produce high-temperature steam or hot water up to 140°C and generating chilled water simultaneously, delivering three to five times more heat per unit of electricity than traditional methods. By managing simultaneous heating and cooling in a single system, they reduce electricity usage by 40–60% and improve efficiency and support 24x7 plant operations.

### **Case Study: ₹115 lakh Annual Gains from 84TR Hybrid Heat Pump**

A leading herbal pharmaceutical company replaced natural gas boilers with a hybrid heat pump system with 84 TR cooling capacity and 930 kW heating capacity. The system meets three key process needs by supplying both hot and chilled water. It delivers 93°C hot water to a plate heat exchanger, which heats fresh water from 25°C to 90°C. This hot water is then supplied to 15 kL extraction tanks used in the herbal extraction process. During operation, return water at 73°C is sent back to the heat pump and reheated to 93°C for reuse. The system also provides 60°C hot water to air handling units through separate heat exchangers to control humidity in process areas. At the same time, return chilled water at 12°C is sent to the heat pump's evaporator, where it is cooled to 7°C, reducing the load on the screw chiller and improving energy efficiency while meeting the plant's comfort cooling needs.

### Key Results:

- Steam savings: 8,521 tonnes/year
- Natural gas savings: 243 Nm<sup>3</sup>/year
- Water savings: 4,482 m<sup>3</sup>/year
- CO<sub>2</sub> reduction: 574 tonnes/year
- Total operational savings: ₹115 lakh/year
- Payback period: < 1.5 years

This single upgrade enables efficient extraction, heating, dehumidification and cooling while significantly cutting costs and emissions.

### The Way Forward for India's API Sector

Improving utility efficiency is one of the fastest ways to cut costs, reduce emissions and strengthen regulatory readiness. Technologies such as hybrid heat pumps provide a practical path to modernise infrastructure while delivering measurable financial and environmental gains. For pharmaceutical companies aiming to lower energy costs and strengthen sustainability performance, evaluating advanced utility solutions such as hybrid heat pumps is a logical starting point. A utility audit or feasibility assessment can quickly identify opportunities to improve efficiency, reduce emissions and unlock long-term savings. Connect with Thermax at [cooling.communications@thermaxglobal.com](mailto:cooling.communications@thermaxglobal.com) to know more.



**Hybrid Heat Pump**

<b>Imports of Bulk drugs by HS codes April-Feb \$ Mn</b>				
HS Code	Description	2025-26	2026-27	%change
17023010	Glucose liquid	0.08	0.09	17.99
17023020	Glucose solid	0.69	0.49	-29.24
17023031	Dextrose,solid	0.62	0.47	-24.52
17023039	Dextrose other than solid	0.90	1.37	52.81
17024039	Dextrose other than solid	0.23	0.13	-41.42
29051410	Ethambutol, ethambutol hcl	3.14	2.83	-9.87
29051420	Salbutamol sulphate	0.26	0.43	67.47
29054300	Mannitol	48.52	48.91	0.80
29054400	D-glucitol (sorbitol)	9.78	9.93	1.57
29071930	Thymol	0.08	0.11	30.39
29072200	Hydroquinone	33.32	31.29	-6.10
29095010	Guaiacol	1.67	3.05	82.43
29124930	Thiacetazone	0.01	0.00	-100.00
29124940	3,4,5-trimethoxy-benzaldehyde	0.40	0.37	-6.40
29154010	Monochloroacetic acide their salts and esters	2.21	1.20	-46.02
29163120	Benzyl Benzoate	0.53	0.73	37.80
29163150	Benzocaine (ethylpara-amino benzoate)	0.04	0.09	148.61
29163400	Phenyl acetic acid	5.80	1.50	-74.16
29171940	Ferrous fumerate	0.04	0.05	18.79
29171970	Ethoxy methylene malonate, diethyl malonate	17.75	13.62	-23.29
29181120	Calcium lactate	0.33	0.26	-21.65
29181320	Metroprolol tartrate	1.36	1.33	-1.90
29181510	Potassium citrate	1.75	0.69	-60.60
29181520	Sodium citrate	1.82	4.22	131.67
29181550	Ferric ammonium citrate	0.02	0.01	-38.66
29181610	Calcium gluconate	8.50	6.46	-23.97
29182110	Salicylic acid	23.70	17.94	-24.29
29182120	Sodium salicylate	0.06	0.12	121.49
29182200	O-acetylsalicylic acid its salts and estrs	0.66	0.62	-6.14
29182310	Methyl salicylate	1.26	0.83	-33.84
29183030	Nalidixic acid	0.64	0.40	-37.64
29199010	Glycerophosphoric acid	0.00	0.04	1689.24
29214600	amfetamine INN and its related apis	0.40	0.33	-16.23
29215110	o phenylanediaamine	15.02	9.70	-35.38
29215120	M-phenylenediaamine (m-di aminobenzene)	3.86	4.04	4.66
29215130	P-phenylenediaamine	4.56	3.73	-18.15
29223100	Amfepra none(inn), methdone & mormethadonesalts	0.00	0.00	1985.61

29224100	Lysine and its esters salts thereof	119.23	97.54	-18.20
29224210	Glutamic acid	0.63	0.75	19.21
29224220	Monosodium glutamate (aginamoto)	52.86	60.36	14.18
29224910	Amino acetic acid (glycine)	23.01	16.97	-26.24
29224920	N-methyl taurine	1.18	3.70	214.28
29225011	Para-amino-salicylic acid	0.35	0.02	-94.57
29225013	Procaine hydrochloride	0.02	0.02	-0.13
29225015	L-tyrosine(p-hydroxyphenylamine)	2.78	3.19	14.92
29225021	Frusemide	0.36	0.48	32.45
29231000	Choline and its salts	2.78	1.83	-34.00
29241100	Meprobamate (inn)	2.03	1.32	-35.06
29242910	Acetanilide	12.11	12.41	2.50
29242960	Pyrazinamide(pyrazine carboxamide)	1.34	0.66	-50.56
29242970	Pretilachlor	2.37	3.24	36.29
29242980	Paracetamol	5.56	10.26	84.34
29262000	1-Cyanoguanidine (dicyandiamide)	65.81	52.23	-20.63
29263000	Fenproporex (inn) & its salts	0.00	0.95	#####
29264000	Alpha-phenylacetoacetonitrile	0.09	0.20	120.12
29280010	Isoniazid	1.72	2.72	58.59
29309040	L-cystine (alpha-amino beta-thiopropionic acid)	16.68	0.00	-100.00
29322010	Coumarin,mthylcoumrn & ehylcoumrn-lactones	0.82	0.58	-30.00
29329300	3 -Carboxy(Para sulpho- phenyl)-5-Pyrazolone	2.57	1.28	-50.02
29331100	Phenazone (antipyrin) and its derivatives	1.23	1.66	34.53
29331910	3-carboxy (para sulpho-phenyl)-5- pyrazolone	0.14	0.60	320.78
29331920	1 (2,5- dichloro-4-sulpho phenyl)-3-methyl 5 Pyrazolone	0.12	0.38	209.00
29331930	3-methyl-1(4-sulpho-O-toluy-5-pyrazolone)	0.00	0.00	-23.94
29331940	Phenylmethylpyrazolone	0.82	0.66	-20.09
29331950	1-phenyl-5-pyrazolone-3-carboxylic acid	0.00	0.71	0.71
29331960	1-(m-sulphophenyl)-3-pyrazolone	0.28	0.49	78.45
29331970	Analgin	4.10	2.59	-36.72
29331980	Oxyphenbutazone	0.01	0.15	1029.11
29332910	Tinidazole	0.25	0.33	27.60

29332920	Metronidazole metronidazole benzoate	10.08	7.84	-22.15
29332930	Mebendazole	0.12	0.17	41.09
29332940	Dimetridazole	0.12	0.00	-96.53
29335200	Malonylurea (barbituric acid) & its salts	4.16	4.71	12.99
29335300	Allobarbitol and other barbitol compounds and its salts	0.19	0.05	-71.56
29335400	Other derivatives of malonylurea (barbituric acid), salts thereof	0.32	1.04	229.09
29335500	Loprazolam, mecloqualone, methaqualone, ziperol, salts thereof	0.00	0.00	-54.20
29335910	Aminophylline(cordophyllin)	0.62	0.16	-74.53
29335920	Trimethoprim	0.25	0.31	26.34
29335940	1-Amino-4-Methyl piperazine	0.01	0.02	54.15
29335950	Bispiribac Sodium( Herbicide)	0.00	0.01	120.61
29339100	Alprazolam, clonazepam & other compounds of zepam, salts thereof	2.25	1.46	-35.00
29339200	Azinphos-methyl (ISO)	0.00	0.00	267.00
29349100	Aminorex, brotizolam and other like compounds, salts thereof	0.03	0.00	-98.46
29349200	Fentanyl	0.54	0.39	-26.85
29349910	Chloro Thiophene-2-Carboxylic Acid	0.69	0.74	6.78
29349930	Pramoxine	0.00	0.01	270.46
29349990	Other Heterocyclic compounds	609.17	626.14	2.79
29351000	N-Methylperfluorooctane sulphonamide	0.02	0.02	9.30
29355090	Other Perfluoro Octane Sulphonamides	0.09	0.97	920.09
29359011	Sulphamethoxazole	0.03	0.04	49.55
29359013	Sulphadiazine	0.61	0.76	24.08
29359014	Sulphadimidine	1.40	1.92	37.34
29359022	Sulphamethiazole	0.00	0.00	-100.00
29359023	Sulphamoxole	0.00	0.00	-100.00
29359024	Sulfamide	0.72	1.20	67.99
29362100	Vitamins A and their derivatives	13.72	19.37	41.21
29362210	Vitamin B1(thiamine, aneurine) & its salt	18.25	22.95	25.76
29362290	Other vitamin B1 and its derivatives	3.38	2.48	-26.58
29362310	Vitamin B2 (riboflavin, lactoflavin) and its salts	10.81	8.35	-22.80

29362390	Other vitamin b2 and its derivatives	4.30	2.67	-37.78
29362400	D-or dl-pantothenic acid (vitamin b3 or vitamin b5) and its derivatives	8.99	10.38	15.40
29362500	Vitamin b6 & its drvts	13.73	12.78	-6.94
29362610	Vitamin b12 (cynocobalamin)	24.50	30.08	22.75
29362690	Other vitamin b12 and its derivatives	1.39	3.24	132.60
29362700	Vitamin c (ascorbic acid) & its drvts	21.97	31.14	41.75
29362800	Vitamin e and its derivatives	39.20	48.76	24.38
29362910	Folic acid (vitamin b9)	3.22	6.05	87.81
29362920	Nctnc acid & nctnmd(niacinamide/niacine	1.71	1.08	-36.60
29362930	Vitamin k (menaphthoquinone b.p.)	2.13	1.86	-12.81
29362940	Vitamin d	13.90	13.79	-0.83
29362950	Vitamin h (biotin)	1.55	1.56	1.08
29362990	Other vitamins and thr drvts	18.10	12.31	-31.99
29369000	Other, incl. natural concentrts	1.07	2.69	152.27
29371100	Somatotropin, its drvts & strctl analoges	0.01	0.00	-54.01
29371200	Insulin and its salts	28.14	47.53	68.94
29371900	Other polypeptide hormones thr drvts & strctl anlgcs	43.93	59.82	36.16
29372100	Cortisone, hydrocortisone, prednisone (dehydrocortisone) and prednisolone and prednisolone (dehydrohydrocortisone)	36.83	34.41	-6.59
29372200	Halogenated drvts of corticosteroidal	26.45	25.79	-2.48
29372300	Oestrogens and progestogens	58.01	49.46	-14.74
29372900	Other steroidal hormones thr drvts and strctl anlgcs	101.01	95.93	-5.03
29375000	Prostaglandins, thromboxanes & leukotrienes thr drvts & strctl anlgcs	6.09	6.18	1.58
29379011	Epinephrine	0.00	0.27	#####
29379019	Other Catecholamine hormones, their derivatives and structural analogues	5.47	3.96	-27.73
29379020	Amino acid Derivatives	10.94	8.38	-23.44
29379090	Other Amino acid Derivatives	53.19	51.80	-2.61
29381000	Rutoside (rutin) and its derivatives	4.56	4.26	-6.48
29389010	Digoxin	0.03	0.16	500.53
29389020	Digitalis glycosides	0.09	0.06	-33.68

29389090	Other glycosides ntrl/rprcd by synthsis &thr slts ethrs drvtvs	70.23	57.80	-17.70
29391100	Concentrates of poppy straw cmpnds of morphin, codeine, codone, the baine, salts thereof	25.84	6.19	-76.04
29392010	Quinine alkaloids	0.65	1.13	75.16
29392020	Quinine hydrochloride	0.00	0.30	7618.35
29392030	Quinine sulphate	0.41	0.65	58.82
29393000	Caffeine and its salts	21.74	33.41	53.66
29394100	Ephedrine & its salts	0.01	0.10	825.79
29394300	Cathine(INN) & its salts	0.00	0.00	223.28
29394400	Norephedrine and its salts	0.00	0.01	1766.46
29394500	Levo Methaphatamine	0.00	0.00	-37.57
29394900	Other ephedrives and thr salts	0.57	0.66	15.88
29395900	Other theophylline and aminophylline thr drvtvs, salts	4.03	4.87	20.72
29396190	Other ergometrine salts	0.12	0.36	200.68
29396210	Ergotamine tartarate	0.74	0.00	-100.00
29396290	Other ergotamine salts	0.04	0.00	-100.00
29396300	Lysergic acid and its salts	0.01	0.00	-100.00
29396900	Other alkaloids of rye ergot & drvtvs	3.07	2.95	-3.97
29397200	Cocaine, ecgonine, levometamfetamin, metamfetamine (INN), metamfetamine racemate; salts, esters and other derivatives thereof	0.26	0.00	-99.77
29397900	Other of Vegetable origin	5.44	9.31	71.12
29398000	Non Vegetable Alkaloids	8.04	4.70	-41.53
29411010	Penicillins and its salts	209.73	103.27	-50.76
29411020	Ampicilline & its salts	0.33	0.51	53.75
29411030	Amoxycilline & its salts	39.91	31.49	-21.09
29411040	Cloxacilline & its salts	0.40	0.97	140.32
29411050	6 - apa	386.80	319.60	-17.37
29411090	Other penicillins & thr drvtvs with a pentcillianic acid strctr slts thereof	77.21	79.95	3.55
29412010	Streptomycins	4.55	4.57	0.56
29412090	Other streptomycine & drvtvs, salts	2.31	2.26	-2.19
29413010	Doxycylime & its salts	19.78	25.35	28.16
29413020	Tetracycline/oxytetra - cycline & hr salts	10.67	11.86	11.13
29413090	Other tetracyclines & thr drvtvs slts	23.31	23.99	2.89

29414000	Chloramphenicol & its drvtvs slts thereof	2.05	0.73	-64.29
29415000	Erthromycin & its drvtvs slts thereof	155.71	179.82	15.49
29419011	Rifampicin	38.68	44.90	16.07
29419013	Rifa S or Rifa S Sodium (Rifaint)	13.16	35.18	167.41
29419014	1-Amino-4-Methyl piperazine (Rifaint)	0.08	0.00	-100.00
29419019	Other rifampicin and its salts	52.42	53.79	2.61
29419020	Cephalexin & its salts	31.45	23.95	-23.86
29419030	Ciprofloxacin & its salts	9.00	4.93	-45.15
29419040	Gentamycin & its salts	8.27	8.06	-2.54
29419050	Neomycin	2.52	3.04	20.79
29419060	Norfloxacin & its salts	11.78	7.66	-34.98
29419090	Other antibiotics	730.15	765.97	4.91
29420011	Cefadroxil	1.40	1.69	20.34
29420012	Ibuprofane	6.39	7.43	16.32
29420013	Nifedipine	0.01	0.40	3919.37
29420014	Ranitidine	0.11	0.19	65.93
29420015	Danes salt of D(-) phenyl glycine	17.31	16.90	-2.36
29420016	Timolo maleate, terbutoline sulphate, imipramine HCl, amitryptiline, Atenolol,Propanolol	24.43	21.28	-12.88
29420021	Timolol maleate	0.31	0.18	-42.24
29420025	Amitryptiline hcl	0.03	0.00	-100.00
29420026	Cysteanune hcl	2.67	3.88	45.19
29420027	Atenolol, propronalol	1.19	1.64	37.38
29420032	Cimetidine	0.65	1.13	74.85
29420033	Oxyclozanide	0.01	0.00	-100.00
29420034	Famotidine	0.20	0.38	84.90
29420090	Other diloxanide furoate, cimetidine, famotidine nes	304.89	282.48	-7.35
96020030	Gelatin capsules,empty	5.44	4.25	-21.82
Grand Total		4055.85	3923.91	-3.25

Exports of Bulk drugs During April-Feb US\$ Mn				
HS Code	Description	2025-26	2026-27	Change%
17023010	Glucose liquid	48.32	51.73	7.06
17023020	Glucose solid	9.99	6.54	-34.53
17023031	Dextrose,solid	16.05	13.71	-14.59
17023039	Dextrose other than solid	0.25	0.34	32.78
17024039	Dextrose other than solid	0.12	0.05	-54.08
29051410	Ethambutol, ethambutol hcl	7.57	4.58	-39.54
29051420	Salbutamol sulphate	11.98	11.01	-8.10
29054300	Mannitol	6.48	6.96	7.38
29054400	D-glucitol (sorbitol)	59.45	60.83	2.32
29071930	Thymol	8.38	6.60	-21.20
29072200	Hydroquinone	9.95	11.85	19.00
29095010	Guaiacol	2.09	1.86	-10.97
29124920	Heliotropin (piperonyl aldehyde)	0.00	0.00	295.22
29124940	3,4,5-trimethoxy-benzaldehyde	2.54	2.00	-21.00
29154010	Monochloroacetic acide their salts and esters	13.56	11.17	-17.66
29163120	Benzyl Benzoate	4.78	3.45	-27.75
29163150	Benzocaine (ethylpara-amino benzoate)	1.57	2.57	63.49
29163400	Phenyl acetic acid	1.07	1.07	0.11
29171940	Ferrous fumerate	7.59	6.67	-12.17
29171970	Ethoxy methylene malonate, diethyl malonate	0.01	0.22	4224.00
29181120	Calcium lactate	0.19	0.12	-36.56
29181320	Metroprolol tartrate	8.96	8.62	-3.78
29181510	Potassium citrate	3.06	1.97	-35.63
29181520	Sodium citrate	11.70	8.17	-30.18
29181550	Ferric ammonium citrate	0.69	0.96	39.99
29181610	Calcium gluconate	6.17	4.77	-22.72
29181620	Ferrous gluconate	1.04	0.58	-43.73
29182110	Salicylic acid	2.51	3.44	37.10
29182120	Sodium salicylate	2.24	2.00	-10.91
29182200	O-acetylsalicylic acid its salts and estrs	1.47	1.40	-4.83
29182310	Methyl salicylate	8.01	7.92	-1.09
29182320	Amino salicylate	0.57	0.53	-7.23
29183030	Nalidixic acid	1.74	0.71	-59.44
29199010	Glycerophosphoric acid	0.03	0.04	25.37
29199030	Iron glycerophosphate	0.04	0.01	-67.30
29214236	Methyl dopa(l-alpha methyl-3, 4-dihydroxyphenylalanine)	0.19	0.18	-4.75
29214600	amfetamine INN and its related apis	30.16	51.35	70.26
29215110	o phenylanediaimine	0.63	1.04	65.92
29215120	M-phenylenediaimine (m-di aminobenzene)	9.76	22.44	129.98
29215130	P-phenylenediaimine	10.34	6.15	-40.46
29215170	Para amini acetanalide	0.33	0.46	40.71
29223100	Amfepra none(inn), methdone & mormethadonesalts	0.51	0.74	43.35

29224100	Lysine and its esters salts thereof	1.67	3.27	96.24
29224210	Glutamic acid	0.17	0.20	18.88
29224220	Monosodium glutamate (aginamoto)	0.61	0.50	-17.62
29224400	Tilidine (INN) and its salts	0.53	0.11	-78.71
29224910	Amino acetic acid (glycine)	23.99	15.56	-35.16
29224920	N-methyl taurine	0.08	0.04	-52.71
29225011	Para-amino-salicylic acid	0.00	0.01	768.03
29225013	Procaine hydrochloride	0.10	0.17	69.85
29225015	L-tyrosine(p-hydroxyphenylamine)	0.01	0.01	-55.14
29225021	Frusemide	17.19	16.21	-5.70
29225024	D0mperid0ne	7.08	6.48	-8.55
29231000	Choline and its salts	10.57	8.57	-18.92
29241100	Meprobamate (inn)	6.22	0.58	-90.70
29242910	Acetanilide	0.30	0.19	-38.74
29242960	Pyrazinamide(pyrazine carboxamide)	4.86	3.34	-31.29
29242970	Pretilachlor	0.04	15.44	34919.03
29242980	Paracetamol	62.54	77.12	23.31
29262000	1-Cyanoguanidine (dicyandiamide)	0.00	0.24	14189.75
29263000	Fenproporex (inn) & its salts	0.04	0.00	-99.41
29280010	Isoniazid	1.02	1.15	12.10
29309040	L-cystine (alpha-amino beta-thiopropionic acid)	3.71	0.00	-100.00
29322010	Coumarin,mthylcoumrn & ehylcoumrn-lactones	8.99	9.62	7.03
29329300	3 -Carboxy(Para sulpho- phenyl)-5-Pyrazololne	0.19	0.41	112.04
29329600	Carbofuran	0.22	0.34	51.95
29331100	Phenazone (antipyrin) and its derivatives	8.57	8.81	2.80
29331910	3-carboxy (para sulpho-phenyl)-5- pyrazolone	1.56	2.11	35.29
29331920	1 (2,5- dichloro-4-sulpho phenyl)-3-methyl 5 Pyrazolone	0.87	6.89	689.41
29331930	3-methyl-1(4-sulpho-O-toluyl-5-pyrazolone)	0.75	0.08	-88.73
29331940	Phenylmethylpyrazolone	0.02	0.03	3.58
29331950	1-phenyl-5-pyrazolone-3-carboxylic acid	0.02	0.00	-87.41
29331960	1-(m-sulphophenyl)-3-pyrazolone	0.04	0.08	69.68
29331970	Analgin	0.08	0.00	-100.00
29332910	Tinidazole	3.15	3.72	17.97
29332920	Metronidazole metronidazole benzoate	15.18	15.79	3.99
29332930	Mebendazole	4.87	6.52	34.06
29332940	Dimetridazole	5.73	4.49	-21.70
29332950	Albendazole	13.05	15.82	21.28
29333914	Chlorpheniramine maleate	5.48	4.79	-12.52
29334100	Levorphanol (inn) and its salts	1.36	0.00	-100.00
29335200	Malonylurea (barbituric acid) & its sals	0.70	1.29	83.79
29335300	Allobarbital and othr barbital compnds andits salts	3.82	2.68	-29.82
29335400	Other derivatives of malonylurea (barbituric acid ), salts thereof	1.28	1.58	23.74
29335910	Aminophylline(cordophylin)	0.67	0.50	-25.24
29335920	Trimethoprim	12.54	11.54	-8.02

29335930	Diethyl carbanazine citrate	1.07	0.24	-77.29
29335940	1-Amino-4-Methyl piperazine	3.32	6.14	84.62
29335950	Bispiribac Sodium( Herbicide)	1.04	6.43	520.41
29339100	Alpra zolam, camazepam & other cmpnds of zepam, salts thereof	18.28	18.92	3.53
29339200	Azinphos-methyl (ISO)	0.11	0.21	100.77
29349100	Aminorex, brotizolam and other like cmpnds, salts thereof	4.72	10.57	123.95
29349200	Fentanyl	0.25	0.54	114.86
29349910	Chloro Thiophene-2-Carboxylic Acid	0.06	0.04	-33.26
29349920	Morpholine	12.94	14.58	12.70
29349930	Pramoxine	0.07	6.48	9814.14
29349990	Other Hetrocyclic compounds	560.94	646.11	15.18
29351000	N-Methylperfluorooctane sulphonamide	0.05	0.28	483.05
29352000	N-Ethylperfluorooctane sulphonamide	0.00	0.04	2038450.00
29355010	Flubendiamide(insecticide)	0.00	0.00	-100.00
29355090	Other Perfluro Octane Suphonomides	2.28	2.43	6.66
29359011	Sulphamethoxazole	30.61	27.05	-11.62
29359012	Sulphafurazole	0.01	0.01	-12.01
29359013	Sulphadiazine	5.44	6.37	17.04
29359014	Sulphadimidine	0.06	0.02	-64.21
29359015	Sulphacetamide	0.01	0.02	141.09
29359022	Sulphamethiazole	2.03	4.06	99.76
29359024	Sulfamide	0.00	0.00	-92.21
29362100	Vitamins a and their derivatives	19.29	19.68	2.01
29362210	Vitamin b1i(thiamine, aneurine) & its salt	9.34	10.61	13.56
29362290	Other vitamin b1i and its drivatives	16.56	11.76	-28.96
29362310	Vitamin b2 (riboflavin, lactoplavin) and its salts	9.30	11.87	27.68
29362390	Other vitamin b2 and its derivatives	0.14	0.17	20.67
29362400	D-or dl-pantothenic acid (vitamin b3 or vitamin b5) and its derivatives	0.83	0.30	-63.46
29362500	Vitamin b6 & its drvtvs	0.26	0.67	155.30
29362610	Vitamin b12 (cynocobalamin)	0.87	1.22	40.89
29362690	Other vitamin b12 and its derivatives	3.65	7.73	112.04
29362700	Vitamin c (ascorbic acid) & its drvtvs	10.37	10.97	5.77
29362800	Vitamin e and its derivatives	17.80	23.58	32.51
29362910	Folic acid (vitamin b9)	4.69	5.87	25.21
29362920	Nctnc acid & nctnmd(niacinamide/niacine)	81.99	72.48	-11.60
29362930	Vitamin k (menaphthonum b.p.)	7.96	6.50	-18.40
29362940	Vitamin d	20.47	25.19	23.07
29362950	Vitamin h (biOlin)	0.67	0.43	-35.26
29362990	Other vitamins and thr drvtvs	18.54	16.44	-11.33
29369000	Other, incl. natural concentrts	41.22	49.96	21.22
29371100	Somatotropin, its drvtvs& strctl analogves	0.24	0.21	-14.30
29371200	Insulin and its salts	34.02	36.70	7.86

29371900	Other polypeptide hormones thr dtvtvs & strctl anlgcs	29.50	38.56	30.71
29372100	Cortisone,hydrocortisone,prednisone (dehydrocortisone)and frednisolone and prdnsln(dehydrohydrocortisone)	11.27	11.78	4.53
29372200	Halgntd drvtvs of corti costeroidal	32.48	30.22	-6.96
29372300	Oestrogens and progestogens	22.14	25.55	15.38
29372900	Othr steroidal hormons thr drvtvs and strctl anlgcs	103.68	110.09	6.18
29373100	Epinehrine	0.01	0.00	-56.05
29375000	Prostaglandins, tiromboxames& leukotrienesthr drvtvs & strctl anlgcs	2.30	1.28	-44.36
29379011	Epinehrine	0.01	0.00	-100.00
29379019	Other Catecholamine hormones, their derivatives and structural analogues	1.39	0.46	-66.99
29379020	Amino acide Derivatives	20.50	10.55	-48.51
29379090	Other Amino acide Derivatives	23.84	20.62	-13.52
29381000	Rutoside (rutin) and its derivatives	0.01	0.00	-83.46
29389010	Digoxin	1.66	1.45	-12.69
29389090	Other glycosides ntrl/rprdcd by synthsis &thr slts ethrs drvtvs	42.73	67.61	58.24
29391100	Concentrates of poppy straw cmpnds of morphin, codeine, codone, the baine, salts thereof	0.95	0.13	-86.08
29392010	Quinine alkaloids	0.00	0.00	104.17
29392020	Quinine hydrochloride	2.50	3.69	47.95
29392030	Quinine sulphate	1.06	0.58	-45.05
29392040	ChlOrOquine phOsphate	1.49	1.62	8.34
29393000	Caffeine and its salts	55.19	68.43	23.98
29394100	Ephedrine & its salts	1.97	1.78	-9.61
29394300	Cathine(INN) & its salts	0.25	0.00	-100.00
29394400	Norephedrine and its salts	2.04	2.44	19.31
29394500	Levo Methaphatamine	0.21	0.07	-66.03
29394900	Other ephedrives and thr salts	2.72	1.47	-45.77
29395900	Other theophylline and aminophylline thr drvtvs, salts	34.10	42.12	23.52
29396110	Ergometrine	0.00	0.00	-100.00
29396190	Other ergometrine salts	0.00	0.00	-100.00
29396210	Ergotamine tartarate	0.00	0.00	-100.00
29396900	Other alkaloids of rye ergot & drvtvs	2.69	1.66	-38.24
29397900	Other of Vegitable origin	104.11	147.23	41.42
29398000	Non Vegetable Alkaloids	16.04	13.55	-15.49
29411010	Penicillins and its salts	0.02	0.14	791.82
29411020	Ampicilline & its salts	23.99	21.00	-12.46
29411030	Amoxycilline & its salts	168.53	129.56	-23.13
29411040	Cloxacilline & its salts	20.58	19.40	-5.77
29411050	6 - apa	0.00	0.03	0.30
29411090	Other penicillins & thr drvtvs wth a pentcillianic acid strctr slts thereof	76.27	62.10	-18.59

29412010	Streptomycins	0.01	0.04	291.13
29412090	Other streptomycine & drvtvs, salts	0.02	0.29	1231.05
29413010	Doxycyclime & its salts	0.55	1.25	125.97
29413020	Tetracycline/oxytetra - cycline & hr salts	1.83	0.95	-47.87
29413090	Other tetracyclines & thr drvtvs slts	0.51	0.29	-42.40
29414000	Chloramphenicol & its drvtvs slts thereof	2.63	1.80	-31.40
29415000	Erthromycin & its drvtvs slts thereof	94.01	84.30	-10.33
29419011	Rifampicin	8.85	12.88	45.52
29419012	3 Formyl Rifa S V(Rifaint)	0.00	0.00	#DIV/0!
29419013	Rifa S or Rifa S Sodium (Rifaint)	0.20	0.00	-100.00
29419019	Other rifampicin and its salts	7.93	3.78	-52.38
29419020	Cephalexin & its salts	8.40	6.09	-27.46
29419030	Ciprofloxacin & its salts	22.05	19.03	-13.70
29419040	Gentamycin & its salts	0.04	0.02	-41.17
29419050	Neomycin	0.03	0.09	178.00
29419060	Norfloxacin & its salts	2.34	1.94	-17.18
29419090	Other antibiotics	505.10	455.51	-9.82
29420011	Cefadroxil	16.52	13.53	-18.11
29420012	Ibuprofane	65.18	64.17	-1.56
29420013	Nifedipine	1.80	2.70	49.80
29420014	Ranitidine	8.67	6.81	-21.47
29420015	Danes salt of D(-) phenyl glycine	0.15	0.00	-100.00
29420016	Timolo maleate, terbutoline sulphate, imipramine HCl, amitryptiline, Atenolol,Propanolol	0.15	0.02	-85.03
29420021	Timolol maleate	4.31	4.34	0.58
29420022	Terbutoline sulphate	1.15	1.29	11.44
29420024	Imipramine hcl	0.57	0.71	23.35
29420025	Amitryptiline hcl	5.17	5.55	7.48
29420026	Cysteanune hcl	0.00	0.00	-94.64
29420027	Atenolol, propronalol	10.05	10.03	-0.22
29420031	Diloxanide furoate	3.02	3.49	15.56
29420032	Cimetidine	0.00	0.08	9894.03
29420033	Oxyclozanide	5.85	8.66	47.98
29420034	Famotidine	12.42	12.11	-2.56
29420090	Other diloxanide furoate, cimetidine, famotidine nes	989.28	987.45	-0.18
96020030	Gelatin capsules,empty	79.66	70.01	-12.11
Grand Total		4148.17	4351.62	4.90



## BULK DRUG MANUFACTURERS ASSOCIATION OF INDIA

**E-Marketing Portal for**

**Indian Bulk Drugs**

[www.bdmaiem.in](http://www.bdmaiem.in)

One Platform, Infinite Possibilities

**A one-stop Platform to Showcase & Source  
APIs & Intermediates, Pallets, Impurities, CDMOs & CRAMS, Consultancy  
& Analytical Services, Vendors – Chemicals /Equipment / Packing and  
More!**

### **Key Features:**

- ❖ **Smart Search** – Find by product, company, CAS number, or HS code
- ❖ **Direct Enquiry System** – Contact suppliers instantly through the portal
- ❖ **Verified Indian Manufacturers** – Reliable, quality-focused companies
- ❖ **Vendor & Service Provider Listings** – Expand your network and reach buyers
- ❖ **Domestic & International Reach** - Promoting make in India Pharma globally

**Join the Portal and Support BDMAI's mission to strengthen  
India's Bulk Drug Industry**

Reach us at:

**C-25, Industrial Estate, Sanathnagar, Hyderabad**  
**[www.bdmai.org](http://www.bdmai.org); [info@bdmai.org](mailto:info@bdmai.org); [ed@bdmai.org](mailto:ed@bdmai.org);**  
**91-40-23706718/4804**